Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

John M S Bartlett; Alison Munro; David A Cameron; Jeremy Thomas; Robin Prescott; Chris J Twelves

doi:10.1200/JCO.2007.14.6597

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

John M S Bartlett, Alison Munro, David A Cameron, Jeremy Thomas, Robin Prescott, Chris J Twelves

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

Original language	English
Pages (from-to)	5027-35
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	26
Issue number	31
DOIs	https://doi.org/10.1200/JCO.2007.14.6597
Publication status	Published - Nov 2008

Keywords

Adult
Aged
Antibiotics, Antineoplastic
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
DNA Topoisomerases, Type II
DNA-Binding Proteins
Disease-Free Survival
Epirubicin
Female
Fluorouracil
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Ki-67 Antigen
Methotrexate
Middle Aged
Patient Selection
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Receptor, erbB-3
Survival Analysis
Time Factors
Tissue Array Analysis
Treatment Outcome
Tumor Markers, Biological

Access to Document

10.1200/JCO.2007.14.6597

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial'. Together they form a unique fingerprint.

Cite this

@article{45a922490364476cb6b3ea2b685b1843,

title = "Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial",

abstract = "Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.",

keywords = "Adult, Aged, Antibiotics, Antineoplastic, Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, DNA Topoisomerases, Type II, DNA-Binding Proteins, Disease-Free Survival, Epirubicin, Female, Fluorouracil, Gene Amplification, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Ki-67 Antigen, Methotrexate, Middle Aged, Patient Selection, Receptor Protein-Tyrosine Kinases, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Receptor, erbB-3, Survival Analysis, Time Factors, Tissue Array Analysis, Treatment Outcome, Tumor Markers, Biological",

author = "Bartlett, {John M S} and Alison Munro and Cameron, {David A} and Jeremy Thomas and Robin Prescott and Twelves, {Chris J}",

year = "2008",

month = nov,

doi = "10.1200/JCO.2007.14.6597",

language = "English",

volume = "26",

pages = "5027--35",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "31",

}

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. / Bartlett, John M S ; Munro, Alison ; Cameron, David A; Thomas, Jeremy; Prescott, Robin; Twelves, Chris J.

In: Journal of Clinical Oncology, Vol. 26, No. 31, 11.2008, p. 5027-35.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

AU - Bartlett, John M S

AU - Munro, Alison

AU - Cameron, David A

AU - Thomas, Jeremy

AU - Prescott, Robin

AU - Twelves, Chris J

PY - 2008/11

Y1 - 2008/11

N2 - Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

AB - Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

KW - Adult

KW - Aged

KW - Antibiotics, Antineoplastic

KW - Antigens, Neoplasm

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Cyclophosphamide

KW - DNA Topoisomerases, Type II

KW - DNA-Binding Proteins

KW - Disease-Free Survival

KW - Epirubicin

KW - Female

KW - Fluorouracil

KW - Gene Amplification

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Ki-67 Antigen

KW - Methotrexate

KW - Middle Aged

KW - Patient Selection

KW - Receptor Protein-Tyrosine Kinases

KW - Receptor, Epidermal Growth Factor

KW - Receptor, erbB-2

KW - Receptor, erbB-3

KW - Survival Analysis

KW - Time Factors

KW - Tissue Array Analysis

KW - Treatment Outcome

KW - Tumor Markers, Biological

UR - http://www.scopus.com/inward/record.url?scp=54849441046&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.6597

DO - 10.1200/JCO.2007.14.6597

M3 - Article

C2 - 18768436

VL - 26

SP - 5027

EP - 5035

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -